The study demonstrated the high immunogenicity of the measles and rubella components and the modest immunogenicity of the mumps component of the MMR vaccine with the active pharmaceutical ingredient from Bio-Manguinhos, which proved non-inferiority to the vaccine with API from GSK. This evidence concerns the gene MRC1 and rubella.